175 related articles for article (PubMed ID: 28100090)
1. Patterns of use of systemic therapies among patients with metastatic melanoma: a retrospective claims database analysis in the United States.
Ma Q; Chen YJ; Hines DM; Munakata J; Batty N; Barber BL; Zhao Z
J Dermatolog Treat; 2017 Sep; 28(6):549-553. PubMed ID: 28100090
[TBL] [Abstract][Full Text] [Related]
2. Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.
Chapman PB; Robert C; Larkin J; Haanen JB; Ribas A; Hogg D; Hamid O; Ascierto PA; Testori A; Lorigan PC; Dummer R; Sosman JA; Flaherty KT; Chang I; Coleman S; Caro I; Hauschild A; McArthur GA
Ann Oncol; 2017 Oct; 28(10):2581-2587. PubMed ID: 28961848
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma.
Patel SP; Kim DW; Bassett RL; Cain S; Washington E; Hwu WJ; Kim KB; Papadopoulos NE; Homsi J; Hwu P; Bedikian AY
Cancer Immunol Immunother; 2017 Oct; 66(10):1359-1366. PubMed ID: 28612140
[TBL] [Abstract][Full Text] [Related]
4. [Dacarbazine, a chemotherapeutic against metastatic melanoma and a reference drug for new treatment modalities].
Koprowska K; Czyż M
Postepy Hig Med Dosw (Online); 2011 Nov; 65():734-51. PubMed ID: 22173438
[TBL] [Abstract][Full Text] [Related]
5. Modelling Comparative Efficacy of Drugs with Different Survival Profiles: Ipilimumab, Vemurafenib and Dacarbazine in Advanced Melanoma.
Lee D; Porter J; Hertel N; Hatswell AJ; Briggs A
BioDrugs; 2016 Aug; 30(4):307-19. PubMed ID: 27177756
[TBL] [Abstract][Full Text] [Related]
6. Costs, resource utilization, and treatment patterns for patients with metastatic melanoma in a commercially insured setting.
Toy EL; Vekeman F; Lewis MC; Oglesby AK; Duh MS
Curr Med Res Opin; 2015 Aug; 31(8):1561-72. PubMed ID: 26086578
[TBL] [Abstract][Full Text] [Related]
7. A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States.
Flaherty L; Hamid O; Linette G; Schuchter L; Hallmeyer S; Gonzalez R; Cowey CL; Pavlick A; Kudrik F; Curti B; Lawson D; Chapman PB; Margolin K; Ribas A; McDermott D; Flaherty K; Cranmer L; Hodi FS; Day BM; Linke R; Hainsworth J
Cancer J; 2014; 20(1):18-24. PubMed ID: 24445759
[TBL] [Abstract][Full Text] [Related]
8. Treatment patterns in advanced melanoma: findings from a survey of European oncologists.
Jones C; Zhao Z; Barber B; Bagijn M; Corrie P; Saltman D
Eur J Cancer Care (Engl); 2015 Nov; 24(6):862-6. PubMed ID: 25988349
[TBL] [Abstract][Full Text] [Related]
9. Current systemic therapies for melanoma.
Palathinkal DM; Sharma TR; Koon HB; Bordeaux JS
Dermatol Surg; 2014 Sep; 40(9):948-63. PubMed ID: 25072125
[TBL] [Abstract][Full Text] [Related]
10. Vemurafenib: in unresectable or metastatic melanoma.
Keating GM
BioDrugs; 2012 Oct; 26(5):325-34. PubMed ID: 22946753
[TBL] [Abstract][Full Text] [Related]
11. Real-world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study.
Middleton MR; Dalle S; Claveau J; Mut P; Hallmeyer S; Plantin P; Highley M; Kotapati S; Le TK; Brokaw J; Abernethy AP
Cancer Med; 2016 Jul; 5(7):1436-43. PubMed ID: 27118102
[TBL] [Abstract][Full Text] [Related]
12. Vemurafenib. Value unclear in metastatic melanoma.
Prescrire Int; 2012 Dec; 21(133):288-90. PubMed ID: 23373092
[TBL] [Abstract][Full Text] [Related]
13. Comparative healthcare costs in patients with metastatic melanoma in the USA.
Chang CL; Schabert VF; Munakata J; Donga P; Abhyankar S; Reyes CM; Yim YM
Melanoma Res; 2015 Aug; 25(4):312-20. PubMed ID: 25882026
[TBL] [Abstract][Full Text] [Related]
14. Upcoming strategies for the treatment of metastatic melanoma.
Spagnolo F; Queirolo P
Arch Dermatol Res; 2012 Apr; 304(3):177-84. PubMed ID: 22350184
[TBL] [Abstract][Full Text] [Related]
15. Long-term survival with modern therapeutic agents against metastatic melanoma-vemurafenib and ipilimumab in a daily life setting.
Lang BM; Peveling-Oberhag A; Faidt D; Hötker AM; Weyer-Elberich V; Grabbe S; Loquai C
Med Oncol; 2018 Jan; 35(3):24. PubMed ID: 29387968
[TBL] [Abstract][Full Text] [Related]
16. Analysis of survival of patients treated with vemurafenib, ipilimumab and dabrafenib for advanced skin melanoma in daily clinical practice (Real-World Data): retrospective analysis of patients treated under drug/reimbursement programmes in Poland in 2013-2016.
Brzozowska M; Wierzba W; Śliwczyński A; Świerkowski M; Potemski P; Marczak M
Melanoma Res; 2018 Feb; 28(1):52-55. PubMed ID: 29120964
[TBL] [Abstract][Full Text] [Related]
17. Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2.
Ma C; Armstrong AW
J Dermatolog Treat; 2014 Oct; 25(5):401-8. PubMed ID: 23763243
[TBL] [Abstract][Full Text] [Related]
18. Treatment patterns and outcomes among patients with metastatic melanoma treated in community practice.
Walker MS; Reyes C; Kerr J; Satram-Hoang S; Stepanski EJ
Int J Dermatol; 2014 Nov; 53(11):e499-506. PubMed ID: 24602078
[TBL] [Abstract][Full Text] [Related]
19. Prognostic markers and tumour growth kinetics in melanoma patients progressing on vemurafenib.
Seifert H; Fisher R; Martin-Liberal J; Edmonds K; Hughes P; Khabra K; Gore M; Larkin J
Melanoma Res; 2016 Apr; 26(2):138-44. PubMed ID: 26684061
[TBL] [Abstract][Full Text] [Related]
20. [Metastatic melanoma: some hope from ipilimumab and vemurafenib].
Piérard-Franchimont C; Piérard GE
Rev Med Liege; 2012 Feb; 67(2):64-8. PubMed ID: 22482234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
